FDA Moves to Unblock One Supplement Ingredient. Why Not CBD?
On Monday, November 16, the FDA proposed letting one ingredient that started life as a drug be sold as a dietary supplement. The ingredient is NAC, short for N-acetyl-L-cysteine. The FDA's announcement calls it the agency's "first use" of a power it had never used before.
CBD is stuck behind that same rule. In 2023, the FDA said CBD needs a new pathway built with Congress. This week it moved to clear a blocked ingredient on its own, one regulation at a time.
Nothing on your shelf changes because of this proposal. It doesn't mention CBD. But it's worth knowing the tool exists, and that the FDA has now picked it up.
What the FDA proposed this week
The rule would reverse NAC's exclusion from the legal definition of a dietary supplement. If it's finalized, NAC products could be "lawfully marketed as dietary supplements, provided that such products are not otherwise in violation" of federal food and drug law, according to the FDA update of November 16, 2026.
It would also create a new regulation called "Dietary Ingredients Not Excluded from the Dietary Supplement Definition." NAC would be the first ingredient on that list. The FDA's own words: "This action is the FDA's first use of our rulemaking authority described in the exclusion provision of the dietary supplement definition."
The proposal ran in the Federal Register on Tuesday, November 17 as document 2026-23351. It is a proposal, not a final rule. Public comments are due by Tuesday, January 19, 2027, under docket FDA-2025-N-2699.
Why was NAC blocked in the first place? According to the Federal Register notice, NAC was approved as a new drug on September 14, 1963. The FDA's November 16 update adds that NAC products sold as supplements "have been sold in the United States for over 30 years" anyway.
The same rule keeps CBD out of supplements
Federal law has a provision, section 201(ff)(3)(B) of the Food, Drug, and Cosmetic Act, that excludes an ingredient from supplements if it's the active ingredient in an approved drug, or the subject of public, substantial clinical investigations as a new drug. The FDA says CBD falls under it. Its CBD questions page (current as of July 16, 2024) states that "THC and CBD products are excluded from the dietary supplement definition."
That same page explains the way out. The exclusion applies unless the FDA "has issued a regulation, after notice and comment, finding that the article would be lawful." Then this line: "To date, no such regulation has been issued for any substance."
The NAC proposal is that kind of regulation. It's the first one the FDA has ever proposed.
What the FDA said about CBD in 2023
On January 26, 2023, the FDA turned down three petitions from industry trade groups asking for exactly this kind of rule for CBD. The agency said that "it is not apparent how CBD products could meet the applicable safety standard for dietary supplements."
The same day, it said where it wanted to go instead. In a statement, Janet Woodcock, then the FDA's Principal Deputy Commissioner, said "a new regulatory pathway for CBD is needed that balances individuals' desire for access to CBD products with the regulatory oversight needed to manage risks. The agency is prepared to work with Congress on this matter."
That statement also listed the tools a new pathway could use: "clear labels, prevention of contaminants, CBD content limits, and measures, such as minimum purchase age, to mitigate the risk of ingestion by children." Read that list twice. It's close to what we ask for: an age limit, testing, honest labels.
There's also a CBD policy waiting at the White House. An FDA notice titled "Cannabidiol (CBD) Products Compliance and Enforcement Policy" reached White House review on Friday, March 13, 2026. As of today, the official RegInfo.gov record still lists it as "Pending Review."
Why it matters with December 11 coming
None of this changes the federal hemp calendar. On Friday, December 11, the rest of the new federal hemp definition takes effect, according to the Congressional Research Service (updated September 28, 2026). That includes a cap of 0.4 milligrams of total THC and other cannabinoids with similar effects, combined, per container, as the same report describes the new definition.
The fix still has to come from Congress. The last extension came in a stopgap funding law, the Continuing Appropriations and Extensions Act, 2027, according to that same CRS report. Federal funding also runs out December 11, and as of November 17 appropriators agreed they need at least a short-term stopgap but hadn't settled how long it should run, Punchbowl News reported.
What the NAC rule changes is the argument. The agency has a process, it has now started using it, and it has said in writing what good rules for CBD could look like.
The supplement industry noticed too. "FDA has opened the door for other ingredients to be considered, but it has not explained how manufacturers can walk through it," Steve Mister, president and CEO of the Council for Responsible Nutrition, said on November 16.
What to tell your lawmakers
Our ask hasn't changed. Regulate the real plant. Ban the fake stuff. Sell only to adults 21 and up. Test every batch and label it honestly. The FDA wrote down several of those items itself in 2023. Congress can finish the job before December 11.
Tell your members of Congress to regulate hemp, not eliminate it. Take action here.
Regulate it. Don't eliminate it.
Sources
- FDA Issues Proposed Rule on NAC Products as Dietary Supplements, U.S. Food and Drug Administration, November 16, 2026
- Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, Federal Register, November 17, 2026 (PDF via GovInfo)
- FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), U.S. Food and Drug Administration, content current as of July 16, 2024
- FDA Issues Response to Three Citizen Petitions Related to CBD and Dietary Supplements, U.S. Food and Drug Administration, January 26, 2023
- FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward, U.S. Food and Drug Administration, January 26, 2023
- Cannabidiol (CBD) Products Compliance and Enforcement Policy, RIN 0910-ZC82, RegInfo.gov (OMB), checked November 18, 2026
- Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (IF13136), Congressional Research Service, updated September 28, 2026
- Top funding issues to watch in the lame duck, Punchbowl News, November 17, 2026
- CRN Welcomes FDA's Proposed NAC Rule, Urges Broader Clarification of Drug Preclusion Framework, Council for Responsible Nutrition, November 16, 2026

